

October 23-26, 2022

## **CivaSheet shows profound improvement in clinical outcomes for pancreatic cancer patients**

CivaTech Oncology Inc., announces CivaSheet® significantly boosts outcomes for borderline resectable and locally advanced pancreatic cancer patients. CivaSheet, an implantable, targeted, shielded radiation device delivers an aggressive targeted dose to the pancreas region following surgical resection. Studies have been conducted in multi-institutional settings with partial support from the NIH/NCI and SBIR programs. This is the first analysis of outcomes.

Between 2017-2020, 19 patients received 3-6 months of chemotherapy, radiation (either conventionally fractionated or SBRT) followed by surgery with CivaSheet placement, mostly prospectively on the Phase 1/2 clinical trial (CivaTech Oncology). During the same time period, data were collected for 16 patients matched by demographics, tumor and treatment factors, who did not have the CivaSheet placed.

Patients followed in this evaluation were all treated at Virginia Commonwealth University (VCU), Massey Cancer Center, and were followed until date of death or last follow up and assessed for local control, disease-free survival, cause-specific survival and overall survival.

Cox proportional hazards models indicated that treatment with the CivaSheet was associated with substantially longer disease-free survival. As shown at the right, more than 25% of patients survived without recurrence for two years and in some cases, much longer. In contrast, no non-CivaSheet patients survived two years without a recurrence or death from disease.

These data are strongly compelling and have significant impact on the increased survival of pancreatic cancer patients, agreed Suzanne Babcock, Chairman of CivaTech Oncology. Patients have no device related toxicity and have a better quality of life without having disease recurrence and subsequent treatment.

Dr. Emma Fields is excited by these results and noted that “many of my patients who had the CivaSheet placed are alive and disease free in long term follow up. I think this is very exciting and can offer hope to our patients.”

About CivaTech Oncology: For more information about CivaSheet or CivaTech Oncology, please visit [www.civatechoncology.com](http://www.civatechoncology.com) or call 919-314-5515 (Randy Harrison).

Taylor RJ, Todor D, Kaplan BJ, Stover W, Fields EC. “CivaSheet intraoperative radiation therapy for pancreatic cancer.” *Brachytherapy* 2022 Mar-Apr;21(2):255-259. Doi:10.1016/j.brachy.2021.10.007  
Emma Fields, MD, Virginia Commonwealth University Massey Cancer Center  
Brian Kaplan, MD, New York University Langone Cancer Center  
Robert H. Aseltine, Jr., PhD, UConn Health , Gregory J. Matthews, PhD, Loyola University




Figure 1: Kaplan-Meier plot presenting disease-free survival in CivaSheet (blue) and non-CivaSheet (red) patients.